⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31015135 | 1.00 | — | — | |
| SCHEMBL907769 | 0.81 | — | — | |
| SCHEMBL28109320 | 0.81 | — | — | |
| SCHEMBL910874 | 0.74 | — | — | |
| SCHEMBL28395247 | 0.74 | — | — | |
| SCHEMBL29237016 | 0.74 | — | — | |
| SCHEMBL31607155 | 0.74 | — | — | |
| SCHEMBL15956513 | 0.70 | — | — | |
| SCHEMBL28395090 | 0.70 | — | — | |
| SCHEMBL1674230 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727922-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727920-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727921-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250250235-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2025-08-07 | — | — | US | disclosed |
| US-12319655-B2 | RAF kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-06-03 | — | — | US | disclosed |
| CN-119604491-A | RAF kinase inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119585242-A | RAF kinase inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2024263460-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024258917-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024258919-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| US-9242969-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242969-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242969-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| EP-2970216-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151616-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151616-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275003-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275003-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275003-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |